With 8.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.1 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $138.805 whereas the lowest price it dropped to was $124.08. The 52-week range on DXCM shows that it touched its highest point at $142.00 and its lowest point at $74.75 during that stretch. It currently has a 1-year price target of $152.77. Beta for the stock currently stands at 1.20.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DXCM was down-trending over the past week, with a drop of -4.87%, but this was down by -10.85% over a month. Three-month performance surged to 1.95% while six-month performance rose 47.41%. The stock lost -0.47% in the past year, while it has gained 0.20% so far this year. A look at the trailing 12-month EPS for DXCM yields 1.55 with Next year EPS estimates of 2.26. For the next quarter, that number is 0.39. This implies an EPS growth rate of 17.43% for this year and 26.48% for next year.
Float and Shares Shorts:
At present, 396.03 million DXCM shares are outstanding with a float of 387.71 million shares on hand for trading. On 2024-04-15, short shares totaled 11.77 million, which was 297.0 higher than short shares on 1710460800. In addition to Mr. Kevin Ronald Sayer as the firm’s Executive Chairman, CEO & President, Mr. Jereme M. Sylvain serves as its Executive VP, CFO & Chief Accounting Officer.
Institutional Ownership:
Through their ownership of 1.00293 of DXCM’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, DXCM reported revenue of $921000000.0 and operating income of $101100000.0. The EBITDA in the recently reported quarter was $189600000.0 and diluted EPS was $0.36.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DXCM since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
